Category: New research findings

Now that Aduhelm (aducanumab) has been approved by the FDA for people with early-stage Alzheimer’s, those with mild cognitive impairment or mild dementia, who will be responsible for the $56,000 annual price tag? A...

A recurring theme of my blog has been that our best shot at attacking Alzheimer’s disease is in the earliest stage, before cognitive impairment has started. We now know that the first pathological signs...

Yesterday I came across an interesting paper from 2013 in Lancet Neurology that adds important information about the case of Auguste D, the first patient diagnosed with what was later called Alzheimer’s disease. I mentioned this...

Today the FDA approved the use of Biogen’s anti-amyloid monoclonal antibody aducanumab for treating early-stage Alzheimer’s disease.  I have mixed feelings about this approval. As someone living with early-stage Alzheimer’s who participated in the aducanumab...

Due to a series of unforeseen events this week, both of our children living in Portland needed additional help caring for their children, our four grandchildren. There is nothing I like better than spending...

A number of studies have previously noted that people with dementia tend to sleep less than those without dementia.  The question has been what is cause and what is effect?  Does getting less sleep promote the...

We all know that Alzheimer’s is an enormous problem. Thousands of researchers around the world are tirelessly searching for clues that might lead to a solution – how to slow or prevent Alzheimer’s.  Reports of...

As I have mentioned in a previous post, the beta-amyloid plaques of Alzheimer’s disease can be seen in the brain up to 20 years before the onset of cognitive decline. The amyloid hypothesis holds...